



## Spermatogonial stem cells: Hope or hype?

An update on spermatogonial stem cell banking and transplantation



Ellen Goossens, PhD

---

---

---

---

---

---


---

---

---

---

## Why ?



2 ESHRE Campus Andrology

16 November 2007

---

---

---

---

---

---


---

---

---

---

## Why ?



3 ESHRE Campus Andrology

16 November 2007

---

---

---

---

---

---


---

---

---

---

# Why ?



---

---

---

---


---

---

---

---

# Why ?



---

---

---

---


---

---

---

---

# Why ?



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---

## Step by step

1. Long term storage
  - Cryopreservation
  - Culture
- (2. Malignant cell removal)
3. Transplantation protocol
4. Efficiency of reproduction
5. Safety of reproduction



---

---

---

---

---

---

---

---

## Step by step

1. Long term storage
  - Cryopreservation
  - Culture
- (2. Malignant cell removal)
3. Transplantation protocol
4. Efficiency of reproduction
5. Safety of reproduction



---

---

---

---


---

---

---

---

## Cryopreservation of cell suspensions



---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

## Cryopreservation of tissue

	No. of grafts	Sclerosis / atrophy	Most advanced cell stage		No. of tubules analysed	No. spz containing tubules	No. of damaged tubules
			spg	spz			
Fresh	28	0 (0%)	-	28 (100%)	1538	354 (23%)	603 (39%)
EG	14	3 (21%)	-	11 (79%)	547	176 (32%)	231 (42%)
DMSO	14	1 (7%)	2 (14%)	11 (79%)	949	308 (32%)	302 (32%)




---

---

---

---

---

---

---

---

---

---

---

---

## Conclusion

- DMSO is the cryoprotectant of choice for banking spermatogonial stem cells
- Tissue cryopreservation seems to result in better fertility preservation
- The protocol needs to be improved to achieve a better maintenance of tissue architecture and spermatogonial stem cell function




---

---

---

---

---

---

---

---


---

---

---

---

## Culture




---

---

---

---

---

---

---

---

---

---

---

---

## Step by step

1. Long term storage
  - Cryopreservation
  - Culture
- (2. Malignant cell removal)
3. Transplantation protocol
4. Efficiency of reproduction
5. Safety of reproduction




---

---

---

---

---

---

---

---

---

---

## Malignant cell removal

REPRODUCED FROM: *THE JOURNAL OF UROLOGY*, 176 (5), MAY 2006


### Intratesticular Transplantation of Testicular Cells from Leukemic Rats Causes Transmission of Leukemia<sup>1</sup>

Kirsi Jahnukainen,<sup>1</sup> Mi Hsu, Cecilia Petersen, Brian Setchell, and Olof Söder

*Andrology*, 18, 446-450 (2006) © 2006 Blackwell Publishing Ltd, DOI: 10.1111/j.1365-2603.2006.01511.x

#### ABSTRACT

A rat T-cell leukemia model was used to study the safety of germ cell transplantation as a means of preventing infertility in males undergoing gonadotoxic cancer treatment. Donor germ cells were harvested from the testes of terminally ill leukemic rats and were either used directly or cryopreserved and thawed before transplantation by rats with intratesticular. All rats transplanted with testicular cells from leukemic donors developed signs of terminal rat T-cell leukemia, whereas control animals remained healthy. Cryopreservation of the donor germ cells caused a 3- to 4-day delay in the terminal phase of leukemia. When a known number of leukemic cells were mixed with germ cells and microinjected into the testis, the rate of appearance of terminal leukemia was directly related to the number of transplanted leukemic lymphoblasts. As few as 20 leukemic cells were able to cause a cancer relapse resulting in terminal leukemia 22 days after transplantation in three of five transplanted animals. Our results demonstrate that germ cell transplantation with the presently used techniques is not safe enough for clinical use. Improved methods for purging individual specimens of cancer cells or totally new approaches with transient xenotransplants may enable us to detect contamination of malignant cells prior to development before this technique can be offered to patients without fear of disease relapse.




---

---

---

---

---

---



---

---

---

---

## Malignant cell removal




---

---

---

---

---

---

---

---

---

---

## Malignant cell removal

Patient	HLA class 1 positivity (%)		Tumour growth in culture (%)		PCR
	Before FACS	After FACS	Before FACS	After FACS	Result
1	12,03	0,09	100	0	positive
2	7,72	0,25	100	0	positive
3	16,31	2,26	100	0	positive
4	5,79	0,49	100	0	positive
5	17,14	0,88	100	0	positive



---

---

---

---

---

---

---

---

## Conclusion

- FACS for HLA-I alone is not efficient enough in decontaminating the cell suspension
- Additional markers will be necessary
- Other decontamination strategies need to be explored



---

---

---

---

---

---

---

---

## Step by step

1. Long term storage
  - Cryopreservation
  - Culture
- (2. Malignant cell removal)
3. Transplantation protocol
4. Efficiency of reproduction
5. Safety of reproduction



---

---

---

---

---

---

---

---





## Spermatogonial stem cell transplantation

### Spermatogenesis following male germ-cell transplantation

(spermatogonia/stem cells/testes/transgenic mice)

RALPH L. BRINSTER\* AND JAMES W. ZIMMERMANN†



25 ESHRE Campus Andrology

16 November 2007

---

---

---

---

---


---

---

---

---

---



3-10  $\mu$ l (~20 stem cells)

---

---

---

---

---

---

---

---

---

---

## Spermatogonial stem cell transplantation

### Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation

Philip F. Brook, Ph.D.,<sup>a</sup> John A. Radford, M.D.,<sup>b</sup> Steven M. Shalst, M.D.,<sup>c</sup>  
Adrian D. Joyce, M.D.,<sup>d</sup> and Roger G. Gosden, D.Sc.<sup>e</sup>



27 ESHRE Campus Andrology

16 November 2007

---

---

---

---

---

---


---

---

---

---

## Intratesticular grafting




---

---

---

---

---

---

---

---

---

---

---

---

## Intratesticular grafting vs SSCT

	N° of transplantations	N° of testes with donor spermatogenesis (%)	Total colony length/testis (mm)
SSCT	9	5 (55)	41.3
Intratesticular grafting	16	16 (100)	125.3
Testes with natural spermatogenesis	2	2 (100)	92.0




---

---

---

---

---

---

---

---


---

---

---

---

## Ectopic (xeno)grafting




---

---

---

---

---

---

---

---


---

---

---

---

## (Xeno)grafting




---

---

---

---

---

---


---

---

---

---

## Prepubertal human to mouse




---

---

---

---

---

---

---

---

---

---

## Conclusion

- SSCT and intratesticular grafting are both resulting in reconstitution of a feasible degree of spermatogenesis
- Intratesticular grafting is easier to perform
- Since xenografting holds a risk for zoonosis, it should only be considered for detecting malignant cells in the testis tissue




---

---

---

---

---

---

---

---

---

---

## Step by step

1. Long term storage
  - Cryopreservation
  - Culture
- (2. Malignant cell removal)
3. Transplantation protocol
4. Efficiency of reproduction
5. Safety of reproduction




---

---

---

---

---

---


---

---

---

---


## Efficiency



In-vivo conception



IVF



ICSI

Assisted reproduction




---

---

---

---

---

---

---

---

---

---

## In-vivo conception



	No. of females with a vaginal plug	Pregnancy rate [%]	No. of foetuses
After transplantation	17	6 (35)	17 (2.8)
Fertile controls	10	9 (90)	76 (8.4)

$P < 0.01$

$P < 0.01$




---

---

---

---

---

---

---

---

---

---

## Offspring



Litter size	Second generation (mean)	Third generation (mean)
After SSCT	5-11 (8.0)	6-8 (7.2)
Fertile controls	5-11 (7.6)	4-8 (5.3)




---

---

---

---

---

---

---

---

---

---

## In-vitro fertilisation



	No. of oocytes	Fertilisation rate (%)	Blastocyst rate (%)
After transplantation	154	88 (57)	24 (27)
Fertile controls	195	155 (79)	88 (57)

$P < 0.00001$

$P < 0.00001$




---

---

---

---

---

---

---


---

---

---

## Vitality

Sperm vitality




---

---

---

---

---

---


---

---

---

---

## Motility semen sample




---

---

---

---

---

---


---

---

---

---

## Motility individual sperm cell




---

---

---

---

---

---

---

---

---

---

## ICSI



	No. of oocytes	Fertilisation rate (%)	Blastocyst rate (%)
After transplantatie	187	57 (69)	17 (30)
Fertile controls	112	38 (61)	14 (37)




---

---

---

---

---

---

---

---

---

---

## Step by step

1. Long term storage
  - Cryopreservation
  - Culture
- (2. Malignant cell removal)
3. Transplantation protocol
4. Efficiency of reproduction
5. Safety of reproduction



---

---

---

---


---

---

---

---

## Safety



---

---

---

---


---

---

---

---

## Safety



---

---

---

---

---

---

---

---

## Hope or hype?

Although a number of questions remain unanswered and several aspects of spermatogonial stem cell banking and transplantation need to be improved, we believe in the applications which are associated with spermatogonial stem cells.



ESHRE Campus Andrology

16 November 2007

---

---

---

---

---


---

---

---

## Clinical cryopreservation program

Keros et al., 2007



Tissue pieces (1-10 mm<sup>3</sup>)

Cryoprotectant: Hank's Balanced Salt Solution + 5% DMSO + 5% HSA



ESHRE Campus Andrology

16 November 2007

---

---

---

---

---

---

---

---

## Clinical experience

### Requests: 15

Accepted : 8 sickle-cell anemia (4)  
leukemia (3)  
idiopathic aplastic anemia (1)

Refused : 1 leukemia (pre-treated)

Parents declined after counseling : 6 leukemia (4)  
sickle-cell anemia (2)



ESHRE Campus Andrology

16 November 2007

---

---

---

---

---

---

---

---



## Transplantation group



ESHRE Campus Andrology  
16 November 2007

---

---

---

---

---

---

---

---